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Synthetic pyrethroid insecticides are a major 
class of insecticides that are replacing home 
and some agricultural use of organophosphorus 
and carbamate insecticides [Agency for Toxic 
Substances and Disease Registry (ATSDR) 
2003]. They are human-made derivatives 
of pyrethrins, which are naturally occurring 
insecticides found in a variety of plants such 
as chrysanthemums (ATSDR 2003). Synthetic 
pyrethroids are designed to be more chemi-
cally potent and environmentally stable than 
natural pyrethrins while still retaining their rela-
tively low mammalian toxicity (Soderlund et al. 
2002). Although they were not used commer-
cially until 1980 (Aprea et al. 1997), by 1982 
pyrethroid insecticides accounted for more than 
30% of the world market (Aprea et al. 1997; 
Leng et al. 1997a). Pyrethroid insecticides are 
the most widely used agents for indoor pest 
control (Go et al. 1999). Those developed since 
the early 1970s have improved photostability 
and minimal volatility, which have enabled 
their successful use in widespread agricultural 
applications (Laws and Hayes 1991). Although 
> 1,000 pyrethroids have been designed 
(ATSDR 2003), the U.S. Environmental 
Protection Agency (EPA) has approved use 
of only about 20 pyrethroid insecticides (U.S. 
EPA 1991), and less than a dozen are used with 
any frequency in the United States. Permethrin 
is the most commonly used pyrethroid insecti-
cide in the United States (ATSDR 2003).
Like many other classes of insecticides, 
the pyrethroid insecticides are acute neu-
rotoxicants (Aldridge 1990; Bradbury and 
Coats 1989; Vijverberg and van den Bercken 
1990), and although dissimilar in structure 
and environmental and biological persis-
tence to p,p´-dichlorodiphenyltrichloroethane 
(DDT), their modes of action are strikingly 
similar (Vijverberg and van den Bercken 1990; 
Vijverberg et al. 1982). Like DDT, pyrethroid 
insecticides modulate the function of voltage-
gated sodium channels (Vijverberg et al. 1982); 
however, pyrethroid insecticides, unlike DDT, 
have short biological half-lives, in the order of 
hours, whereas DDT has a half-life of many 
years. Specifically, pyrethroid insecticides alter 
the permeability of excited nerve cells to sodium 
ions and cause repetitive nerve impulses that 
can vary between a few dozen for the less toxic 
non-cyano-substituted pyrethroid insecticides 
(type I) to up to 1,000 for the more toxic cyano- 
substituted pyrethroid insecticide (type II) 
(Aldridge 1990; Bradbury and Coats 1989; 
Vijverberg and van den Bercken 1990). They 
also have other neurobiologic actions, includ-
ing effects on central γ-amino butyric acid, 
noradrenergic, dopaminergic, and cholinergic 
neurotransmission (Mandhane and Chopde 
1997). In general, pyrethroid insecticides are 
considered among the lower-human-toxicity 
insecticides because mammals have higher lev-
els than do insects of the enzymes that detoxify 
pyrethroid insecticides; thus, pyrethroid insec-
ticides are rapidly metabolized and excreted in 
mammalian systems (Narahashi 2001).
Although studies in humans demonstrate 
that pyrethroid insecticides are absorbed 
readily after exposure by inhalation, oral, 
and dermal routes (ATSDR 2003), the pri-
mary exposure route in the general popula-
tion is thought to be through dietary intake 
(ATSDR 2003). However, because of their 
burgeoning use in common household insec-
ticide products such as spray insecticides, 
aerosol bombs, and pet shampoos (ATSDR 
2003), low-level episodic exposures from 
household use are probable. Exposures from 
household use in colder areas likely occur 
in the spring and summer when household 
pests are at their peak; however, in warmer 
climates, pyrethroid insecticides may be used 
in homes year-round. Furthermore, the use 
of pyrethroid insecticides, particularly per-
methrin, in lice treatments and shampoos 
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Ba c k g r o u n d: Pyrethroid insecticides are the most commonly used residential insecticides in the 
United States.
oBjectives: Our objective was to assess human exposure via biomonitoring to pyrethroid insecti-
cides in a representative sample of the general U.S. population ≥ 6 years of age. 
Me t h o d s : By using isotope-dilution high-performance liquid chromatography/electrospray 
chemical ionization/tandem mass spectrometry, we measured five urinary metabolites of pyrethroid 
insecticides in 5,046 samples collected as a part of the 1999–2002 National Health and Nutrition 
Examination Survey (NHANES). Univariate, multivariate, and Pearson correlation analyses were 
performed using SUDAAN and SAS software, incorporating the appropriate sample weights into 
the analyses. Multivariate analyses included age, sex, race/ethnicity, creatinine, fasting status, and 
urine collection time as covariates.
re s u l t s: We detected 3-phenoxybenzoic acid (3PBA), a metabolite common to many pyrethroid 
insecticides, in more than 70% of the samples. The least-squares geometric mean (LSGM) concen-
tration (corrected for covariates) of 3PBA and the frequency of detection increased from 1999–2000 
(0.292 ng/mL) to 2001–2002 (0.318 ng/mL) but not significantly. Non-Hispanic blacks had 
significantly higher LSGM 3PBA concentrations than did non-Hispanic whites and Mexican 
Americans in the 2001–2002 survey period and in the combined 4-year survey periods but not in 
the 1999–2000 survey period. Children had significantly higher LSGM concentrations of 3PBA 
than did adolescents in both NHANES periods and than adults in NHANES 1999–2000. Cis- and 
trans-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane-1-carboxylic acid were highly correlated with 
each other and with 3PBA, suggesting that urinary 3PBA was derived primarily from exposure to 
permethrin, cypermethrin, or their degradates.
co n c l u s i o n s: Pyrethroid insecticide exposure in the U.S. population is widespread, and the pres-
ence of its metabolites in the urine of U.S. residents indicates that children may have higher expo-
sures than adolescents and adults.
key w o r d s : general population, insecticide, NHANES, pyrethroid, 3-phenoxybenzoic acid, urine. 
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may allow for direct exposure to certain pyre-
throid insecticides in children.
Mammalian animal studies have identified 
several important metabolites of pyrethroid 
insecticides. 3-Phenoxybenzoic acid (3PBA) is 
a metabolite of many pyrethroid insecticides 
resulting from the oxidation of the hydro-
lytic product of many pyrethroid insecticides, 
3-phenoxybenzyl alcohol (Figure 1, Table 1). 
Similarly, 4-fluoro-3-phenoxybenzoic acid 
(4F3PBA) is a metabolite of the fluorine-
substituted pyrethroid insecticide cyfluthrin. 
Chrysanthemic acid derivatives are also 
obtained after pyrethroid insecticide metabolism 
(Figure 1). Cis- and trans-(2,2-dichlorovinyl)-
2,2-dimethylcyclopropane-1-carboxylic acid 
(cis- and trans-DCCA) are metabolites of the 
chlorinated pyrethroid insecticides permethrin, 
cypermethrin, and cyfluthrin. Cis-(2,2-
dibromovinyl)-2,2-dimethylcyclopropane-
1-carboxylic acid (cis-DBCA) is a selective 
metabolite of deltamethrin. Human dosing 
studies of cypermethrin isomers (Eadsforth and 
Baldwin 1983; Eadsforth et al. 1988; Woollen 
et al. 1992) and cyfluthrin (Leng et al. 1997b) 
and occupational exposure studies (Aprea et al. 
1997; Hardt and Angerer 2003; Leng et al. 
1996) have confirmed that many of these 
metabolites are important markers of pyrethroid 
insecticide exposure in humans (Leng et al. 
1997b). The presence of metabolites represent-
ing both halves of the pyrethroid insecticide 
molecule can indicate the source pyrethroid 
insecticides for the metabolites.
We report urinary concentrations of 
five metabolites of pyrethroid insecticides in 
1,998 persons of the general U.S. population 
6–59 years of age in 1999 and 2000 and in 
3,048 persons ≥ 6 years of age in 2001 and 
2002. Specifically, we report urinary concentra-
tions of 3PBA, a common metabolite of up to 
18 synthetic pyrethroid insecticides; 4F3PBA, 
a metabolite of cyfluthrin; cis-DCCA and 
trans-DCCA, geometric isomeric metabolites 
of permethrin, cypermethrin, and cyfluthrin; 
and cis-DBCA, a metabolite of delta  methrin 
(Figure 2). The data we report are representa-
tive of the civilian, non  institutionalized U.S. 
population and are stratified by age, sex, and 
race/ethnicity. We also evaluated fasting dura-
tion and time of sample collection (i.e., morn-
ing, afternoon, evening) to see if the metabolite 
concentrations may have been influenced by 
these factors.
Methods
Study population. The National Health and 
Nutrition Examination Survey (NHANES), 
conducted by the National Center for Health 
Statistics (NCHS) of the Centers for Disease 
Control and Prevention (CDC), is designed to 
measure the health and nutrition status of the 
civilian noninstitutionalized U.S. population 
(CDC 2003). In 1999, NHANES became 
a continuous survey, fielded on an ongoing 
basis. Each year of data collection is based on 
a representative sample, which covers all ages 
of the civilian noninstitutionalized popula-
tion. Public-use data files have been released 
in 2-year groupings (cycles). In this study, 
national population estimates for pyrethroid 
metabolites and estimates for the three largest 
race/ethnicity subgroups in the U.S. popula-
tion (non-Hispanic white, non-Hispanic black, 
and Mexican American) are derived from 
two 2-year cycles of the survey, NHANES 
Table 1. Common pyrethroid insecticides and their corresponding urinary metabolites.
Metabolite
Pyrethroid insecticide 3PBA cis-DCCA trans-DCCA 4F3PBA cis-DBCA
Permethrin X X X
Cypermethrin X X X
Cyfluthrin X X X
Deltamethrin X X
Allethrin X
Resmethrin X
Fenvalerate X
Some metabolites are excreted as glucuronide conjugates, which we liberated before analysis; only the liberated 
metabolites are listed here. 
Figure 1. General metabolism of both type I and type II pyrethroid insecticides. Type I insecticides have an 
R2 substitution of H, and type II insecticides have an R2 substitution of CN (cyano group).
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1999–2000 and NHANES 2001–2002. 
The study was reviewed and approved by the 
Ethical Review Board at the NCHS and com-
plied with all national and international guide-
lines on research involving human subjects.
The sampling scheme for NHANES is 
based on a complex multistage area probabil-
ity design, which includes selection of pri-
mary sampling units (counties), household 
segments within the counties, and sample 
persons from selected households. In 1999 
and 2000, people 12–19 years and ≥ 60 years 
of age, non-Hispanic blacks, and Mexican 
Americans were oversampled. Low-income 
white Americans were oversampled beginning 
in 2000. Data were collected through a house-
hold interview and a standardized physical 
examination that was conducted in a mobile 
examination center. Spot urine specimens 
were collected from each participant ≥ 6 years 
of age during one of three daily examination 
periods. Sociodemographic information and 
medical histories of the survey participant and 
the family were collected during the house-
hold interview. Fasting duration was also col-
lected from each participant.
NHANES 1999–2000 was conducted 
in 26 locations throughout the United States 
and included examinations of 9,282 people; 
NHANES 2001–2002 was conducted in 30 
locations and included examinations of 10,000 
people. For the pyrethroid metabolites in the 
first NHANES cycle, we conducted measure-
ments on a subset of participants based on 
a random one-half sample of children 6–11 
years of age in 1999 and 2000, a random one-
quarter sample of people 12–59 years of age 
in 1999, and a random one-third sample of 
people 12–59 years of age in 2000. For the 
second NHANES cycle, we conducted meas-
ure  ments on a subset of participants based on 
a one-half sample of children 6–11 years of age 
Table 2. Urinary concentrations of 3PBA in the general U.S. population, NHANES 1999–2002. 
Category/ 
survey years
GM (95% confidence 
interval)
Selected percentile (95% confidence interval) Sample 
size (n)
Weighted 
detection (%) 50th 75th 90th 95th
Total
1999–2000a 0.292 (0.247–0.345) 0.25 (0.19–0.32) 0.73 (0.59–0.85) 1.75 (1.49–2.16) 4.33 (2.62–6.30) 1,998 66.5
2001–2002a 0.318 (0.275–0.368) 0.27 (0.22–0.34) 0.70 (0.57–0.81) 1.73 (1.49–2.16) 3.54 (2.69–5.25) 3,048 75.4
1999–2000b 0.261 (0.224–0.304) 0.25 (0.20–0.28) 0.55 (0.46–0.63) 1.40 (1.13–1.73) 3.19 (2.16–4.55) 1,998 66.5
2001–2002b 0.324 (0.284–0.371) 0.29 (0.25–0.34) 0.60 (0.51–0.75) 1.54 (1.26–1.91) 3.35 (2.50–4.92) 3,046 75.4
Age group
6–11 years
1999–2000a 0.417 (0.292–0.595) 0.32 (0.21–0.49) 10.12 (0.70–1.60) 4.18 (2.02–6.54) 8.63 (3.89–71.1) 483 71.9
2001–2002a 0.325 (0.260–0.406) 0.30 (0.20–0.42) 0.76 (0.57–1.05) 1.81 (1.42–2.78) 3.38 (2.25–4.12) 580 75.2
1999–2000b 0.450 (0.299–0.677) 0.30 (0.19–0.44) 0.89 (0.57–1.35) 2.59 (1.41–5.49) 7.20 (1.88–64.0) 483 71.9
2001–2002b 0.423 (0.335–0.534) 0.33 (0.25–0.41) 0.66 (0.49–1.06) 1.81 (1.28–2.58) 3.04 (2.00–4.09) 580 75.2
12–19 years
1999–2000a 0.336 (0.265–0.427) 0.29 (0.20–0.44) 0.87 (0.62–1.04) 1.93 (1.49–2.90) 4.33 (1.83–11.1) 682 73.2
2001–2002a 0.353 (0.288–0.434) 0.30 (0.25–0.39) 0.80 (0.56–1.13) 1.86 (1.48–2.35) 3.45 (2.14–6.69) 831 79.8
1999–2000b 0.227 (0.178–0.290) 0.16 (0.12–0.20) 0.39 (0.29–0.52) 1.16 (0.71–1.39) 1.65 (1.25–4.21) 682 73.2
2001–2002b 0.274 (0.229–0.328) 0.21 (0.18–0.25) 0.46 (0.35–0.61) 1.01 (0.72–1.46) 1.69 (1.10–5.48) 830 79.8
20–59 years
1999–2000a 0.267 (0.227–0.314) 0.23 (0.16–0.30) 0.64 (0.51–0.82) 1.49 (1.25–1.78) 3.21 (2.04–5.41) 833 64.2
2001–2002a 0.314 (0.271–0.364) 0.27 (0.22–0.34) 0.67 (0.53–0.78) 1.65 (1.27–2.34) 3.25 (2.51–6.16) 1,128 75.8
1999–2000b 0.246 (0.216–0.278) 0.26 (0.22–0.29) 0.55 (0.46–0.63) 1.30 (1.04–1.62) 2.86 (1.97–4.18) 833 64.2
2001–2002b 0.311 (0.271–0.357) 0.30 (0.26–0.35) 0.60 (0.50–0.75) 1.59 (1.15–2.46) 3.43 (2.37–5.11) 1,128 75.8
≥ 60 years
2001–2002a 0.303 (0.233–0.394) 0.25 (0.18–0.35) 0.69 (0.49–1.10) 2.03 (1.45–3.68) 5.16 (2.77–6.61) 509 70.3
2001–2002a 0.372 (0.301–0.462) 0.32 (0.24–0.41) 0.73 (0.54–1.02) 2.16 (1.28–3.50) 4.06 (2.44–6.15) 508 70.3
Sex
Male
1999–2000a 0.273 (0.226–0.330) 0.25 (0.18–0.33) 0.71 (0.57–0.82) 1.49 (1.29–1.73) 2.41 (1.92–3.79) 974 65.3
2001–2002a 0.326 (0.281–0.379) 0.30 (0.23–0.36) 0.69 (0.57–0.75) 1.60 (1.37–2.15) 3.23 (2.56–5.25) 1,429 77.8
1999–2000b 0.210 (0.173–0.253) 0.19 (0.15–0.25) 0.51 (0.39–0.59) 1.13 (0.86–1.49) 1.85 (1.49–2.53) 974 65.3
2001–2002b 0.269 (0.233–0.310) 0.24 (0.20–0.28) 0.50 (0.43–0.58) 1.28 (1.05–1.59) 3.00 (1.74–4.00) 1,429 77.8
Female
1999–2000a 0.311 (0.253–0.384) 0.25 (0.19–0.34) 0.74 (0.51–0.99) 2.30 (1.63–3.36) 6.03 (3.27–11.8) 1,024 67.7
2001–2002a 0.311 (0.260–0.371) 0.25 (0.20–0.32) 0.73 (0.55–0.92) 1.81 (1.53–2.47) 3.76 (2.51–6.55) 1,619 73.1
1999–2000b 0.323 (0.270–0.387) 0.28 (0.24–0.34) 0.60 (0.47–0.71) 1.88 (1.31–2.86) 5.03 (3.08–6.90) 1,024 67.7
2001–2002b 0.388 (0.331–0.455) 0.33 (0.28–0.41) 0.73 (0.56–0.93) 1.84 (1.45–2.35) 4.43 (2.62–5.59) 1,617 73.1
Race/ethnicity
Non-Hispanic white
1999–2000a 0.288 (0.233–0.355) 0.24 (0.16–0.32) 0.71 (0.53–0.85) 1.78 (1.41–3.05) 5.34 (2.62–8.43) 603 65.1
2001–2002a 0.297 (0.248–0.355) 0.24 (0.19–0.32) 0.60 (0.49–0.78) 1.75 (1.46–2.34) 3.70 (2.52–6.16) 1,281 73
1999–2000b 0.272 (0.225–0.329) 0.28 (0.23–0.34) 0.63 (0.51–0.80) 1.88 (1.35–2.53) 4.44 (2.29–5.93) 603 65.1
2001–2002b 0.321 (0.274–0.377) 0.31 (0.26–0.36) 0.67 (0.53–0.91) 1.84 (1.46–2.62) 4.43 (2.63–6.04) 1,280 73
Mexican American
1999–2000a 0.260 (0.230–0.295) 0.23 (0.19–0.27) 0.60 (0.43–0.75) 1.35 (1.16–1.53) 2.18 (1.53–3.26) 697 68.1
2001–2002a 0.290 (0.233–0.361) 0.26 (0.19–0.35) 0.65 (0.49–0.81) 1.26 (0.86–2.17) 2.65 (1.50–3.44) 767 76
1999–2000b 0.234 (0.202–0.272) 0.16 (0.13–0.19) 0.31 (0.27–0.39) 0.64 (0.49–0.95) 1.06 (0.67–1.71) 697 68.1
2001–2002b 0.274 (0.230–0.328) 0.20 (0.18–0.24) 0.39 (0.31–0.48) 0.73 (0.58–0.96) 1.18 (0.79–1.98) 767 76
Non-Hispanic black
1999–2000a 0.454 (0.352–0.586) 0.45 (0.35–0.61) 1.13 (0.75–1.46) 2.32 (1.45–5.35) 5.35 (2.32–21.1) 524 80.3
2001–2002a 0.507 (0.430–0.599) 0.52 (0.44–0.63) 0.98 (0.84–10.20) 2.03 (1.72–2.52) 3.86 (3.05–5.84) 776 88.7
1999–2000b 0.309 (0.238–0.401) 0.25 (0.20–0.32) 0.58 (0.39–0.78) 1.36 (0.89–2.79) 3.43 (1.39–5.44) 524 80.3
2001–2002b 0.374 (0.308–0.455) 0.32 (0.25–0.39) 0.59 (0.50–0.69) 1.29 (0.93–1.66) 2.62 (1.58–3.26) 775 88.7
< LOD indicates less than the LOD for the uncorrected urine values, which may vary for some chemicals by year. n-Values may differ because some information was missing for a 
  particular subgroup.
aVolume-based concentrations (ng/mL). bCreatinine-adjusted concentrations (μg/g creatinine). Pyrethroid metabolites in the U.S. population
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in 2001, a random one-third sample of chil-
dren 6–11 years of age in 2002, and a random 
one-third sample of people ≥ 12 years of age in 
2001 and 2002. Because the subset was a ran-
dom selection from the entire set, the ability of 
the samples tested to accurately represent the 
U.S. population was maintained.
Laboratory methods. The urine for pyre-
throid measurements was aliquoted at the 
collection site, stored cold (2–4°C) or frozen 
until shipment to CDC’s National Center for 
Environmental Health laboratory on dry ice. 
Urinary creatinine concentrations were deter-
mined using an automated colorimetric method 
based on a modified Jaffe reaction (Jaffe 1886) 
on a Beckman Synchron AS/ASTRA clinical 
analyzer (Beckman Instruments, Inc., Brea, 
CA) at the Fairview University Medical Center 
(Minneapolis, MN). We analyzed urine sam-
ples for pyrethroid metabolites using established 
methodology (Baker et al. 2004; Olsson et al. 
2004). Briefly, 2 mL urine was spiked with 
an internal standard mixture consisting of iso-
topically labeled 3PBA and trans-DCCA and 
incubated with β-glucuronidase/sulfatase to 
liberate conjugated metabolites. The hydro-
lysates were extracted using OASIS HLB 
(Waters Corp., Milford, MA) mixed-mode 
solid-phase extraction cartridges. The cartridges 
were washed with 5% methanol in a 0.1% 
acetic acid solution, and the metabolites were 
eluted using methanol. The extracts were con-
centrated and analyzed using high-performance 
liquid chromatography/electrospray chemical 
ionization/tandem mass spectrometry. 3PBA 
and trans-DCCA were quantified using iso-
tope dilution calibration, whereas 4F3PBA, 
cis-DCCA, and cis-DBCA were quantified using 
the labeled 3PBA, labeled trans-DCCA, and 
labeled trans-DCCA, respectively, as internal 
standards. Positive and negative control samples 
represented 10% of the samples analyzed to 
ensure proper method operation. Metabolite 
concentrations were adjusted using creatinine 
concentrations to correct for variable urine dilu-
tions in the “spot” urine samples. Both labora-
tories and methods were certified according to 
guidelines set forth in the Clinical Laboratory 
Improvement Amendment of 1988.
Demographic and other covariates. Age 
was reported at the time of the household 
interview as the age in years at the last birth-
day. Age categories used in our statistical anal-
yses were 6–11, 12–19, and 20–59 years for 
1999–2002, and ≥ 60 years for 2001–2002. 
A composite race/ethnicity variable based on 
self-reported race and ethnicity was created 
to define three major racial/ethnic groups: 
non-Hispanic black, non-Hispanic white, and 
Mexican American. Individuals from other 
racial/ethnic groups were included in the total 
estimates reported here; however, no separate 
demographic breakdown is provided.
Traditionally, creatinine concentrations 
have been used to adjust spot urine samples for 
variable dilution caused by the different hydra-
tion states of the sample donor. Because crea-
tinine concentrations vary with age, sex, and 
race/ethnicity, creatinine adjustment in diverse 
populations would not be valid for compari-
sons of pyrethroid insecticide metabolite con-
centrations among the demographic groups 
(Barr et al. 2005). To overcome this limita-
tion and allow for an appropriate compari-
son of metabolite concentrations among the 
demographic groups, we also used creatinine 
as a covariate in statistical models (Barr et al. 
2005). By using this model, we appropriately 
corrected for covariate effects on the creatinine 
concentrations while reducing the variability 
caused by urine dilution of spot samples.
Statistical analysis. Survey-specific sam-
ple weights calculated for the specified ran-
dom subset were used in statistical analyses. 
SUDAAN (RTI International, Research 
Triangle Park, NC) incorporates the NHANES 
sampling weights and adjusts for the complex 
sample design of the survey. Sample weights 
take into account the unequal probabilities of 
selection, resulting from the cluster design and 
the planned oversampling of certain subgroups. 
Oversampling of adolescents, the elderly, non-
Hispanic blacks, and Mexican Americans 
necessitated the use of sampling weights in all 
analyses to produce national estimates of preva-
lence and associated variances.
Parametric statistics were performed only 
on metabolites with sufficient frequency of 
detection (> 60%) to avoid undue influence 
on the estimates caused by imputed values in 
the analyses; thus, 3PBA was the only metabo-
lite parametrically analyzed. Data distribution, 
univariate, bivariate, and multivariate statistics 
were evaluated. Arithmetic means, geometric 
means (GMs), least-squares geometric means 
(LSGMs), weighted Pearson correlation coef-
ficients, and percentiles of 3PBA, cis-DCCA, 
and trans-DCCA concentrations were calcu-
lated using SAS (release 9.1; SAS Institute Inc., 
Cary, NC) and SUDAAN (release 9.0). For 
comparing populations, LSGMs corrected the 
GMs for the common statistical variables tested 
(i.e., age group, race/ethnicity, sex, and time of 
sample collection, and fasting) that showed 
correlations in bivariate statistics or could 
potentially influence comparisons. For concen-
trations below the analytic limits of detection 
(LODs), a value equal to the LOD divided by 
the square root of 2 was used (Hornung and 
Reed 1990). The LODs were 0.1 ng/mL for 
3PBA, 0.2 ng/mL for 4F3PBA, 0.1 ng/mL 
for cis-DCCA, 0.4 ng/mL for trans-DCCA, 
and 0.1 ng/mL for cis-DBCA. Differences in 
LSGMs among demographic groups were con-
sidered to be significant when p < 0.05.
Results
Table 2 shows distribution percentiles of 
concentrations of 3PBA, both volume based 
and creatinine adjusted. Of the metabolites 
measured, 3PBA was the most frequently 
detected. Overall, 3PBA was detected more 
frequently in samples collected in 2001 and 
2002 (75.4%) than in samples collected in 
1999–2000 (66.5%; p = 0.07). Univariate 
analysis results showed that the GM of the 
3PBA concentrations among race (p = 0.003 
for 1999–2000; p < 0.001 for 2001–2002) 
and age group (p = 0.003 for 1999–2000 
only) were significantly different.
For the 1999–2000 survey period, in the 
final multivariate model, age group and time 
of sample collection were the only signifi-
cant variables in addition to log-transformed 
creatinine. The LSGM 3PBA concentration 
was higher for children than for adolescents 
(p = 0.009) (Figure 3A). Samples collected 
Figure 3. LSGM concentrations of age (A), sample collection time (B), and race (C: MA, Mexican American; NHB, non-Hispanic black; NHW, non-Hispanic white). 
*p < 0.05. **0.05 < p < 0.1. 
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during the morning sampling period had sig-
nificantly higher 3PBA concentrations than 
did those collected in the afternoon (p = 
–0.002) and evening (p < 0.001) sampling 
periods (Figure 3B).
For the 2001–2002 survey period, race 
(p = 0.008; Figure 3C) and sample collection 
time (p = 0.036; Figure 3B) were significant in 
the final model, but not age group or sex. The 
LSGM 3PBA concentration of non-Hispanic 
blacks was higher than those of non-Hispanic 
whites (p = 0.039) and Mexican Americans 
(p = 0.025) (Figure 3C). 3PBA concentra-
tions in samples collected during the evening 
sampling period were significantly lower than 
those collected in the morning (p = 0.001) 
and afternoon (p = 0.007) (Figure 3B).
For combined survey periods (1999–2002), 
race, age, and time of collection were all signifi-
cant in the final model. Non-Hispanic blacks 
had a higher LSGM 3PBA concentrations than 
did non-Hispanic whites (p = 0.0096) and 
Mexican Americans (p < 0.0001). Children had 
higher LSGM 3PBA concentration than did 
adolescents (p = 0.001) and adults (p = 0.0014); 
however, we observed no difference between 
adolescents and adults. 3PBA concentrations in 
samples collected during the evening sampling 
period were significantly lower than those col-
lected in the morning (p = 0.02) and afternoon 
(p = 0.03; Figure 3B). Fasting duration was not 
a significant variable in either survey period or 
in the combined survey periods.
Table 3. Urinary concentrations of cis-DCCA in the general U.S. population, NHANES 1999–2002.
Category/survey 
years
GM (95%  
confidence interval)
Selected percentile (95% confidence interval) Sample 
size (n)
Weighted 
detection (%) 50th 75th 90th 95th
Total
1999–2000a NC < LOD 0.27 (0.22–0.34) 0.60 (0.49–0.71) 1.12 (0.77–1.68) 1,951 46.7
2001–2002a NC < LOD 0.17 (0.13–0.23) 0.51 (0.41–0.67) 0.91 (0.80–1.10) 3,048 32.4
1999–2000b NC < LOD 0.26 (0.23–0.29) 0.54 (0.44–0.70) 1.12 (0.69–1.59) 1,951 46.7
2001–2002b NC < LOD 0.23 (0.21–0.25) 0.46 (0.42–0.54) 0.90 (0.75–1.04) 3,046 32.4
Age group
6–11 years
1999–2000a NC < LOD 0.33 (0.21–0.55) 0.74 (0.58–1.53) 1.77 (0.68–3.15) 468 46.6
2001–2002a NC < LOD 0.11 (< LOD-0.20) 0.37 (0.28–0.61) 0.73 (0.49–0.87) 580 26.4
1999–2000b NC < LOD 0.26 (0.19–0.40) 0.63 (0.40–1.38) 1.38 (0.59–1.80) 468 46.6
2001–2002b NC < LOD 0.21 (< LOD-0.25) 0.40 (0.32–0.58) 0.70 (0.54–0.77) 580 26.4
12–19 years
1999–2000a NC < LOD 0.30 (0.20–0.41) 0.67 (0.46–1.11) 1.44 (0.67–2.21) 667 48
2001–2002a NC < LOD 0.16 (< LOD–0.21) 0.44 (0.30–0.63) 0.73 (0.63–0.92) 831 31.7
1999–2000b NC < LOD 0.16 (0.13–0.21) 0.32 (0.25–0.45) 0.57 (0.32–1.24) 667 48
2001–2002b NC < LOD 0.13 (< LOD-0.18) 0.27 (0.21–0.33) 0.38 (0.29–0.56) 830 31.7
20–59 years
1999–2000a NC < LOD 0.26 (0.20–0.33) 0.57 (0.43–0.69) 1.07 (0.67–1.80) 816 46.5
2001–2002a NC < LOD 0.17 (0.12–0.23) 0.51 (0.40–0.74) 0.96 (0.79–1.28) 1,128 32.6
1999–2000b NC < LOD 0.29 (0.26–0.32) 0.55 (0.44–1.06) 1.33 (0.83–1.75) 816 46.5
2001–2002b NC < LOD 0.26 (0.24–0.28) 0.58 (0.44–0.72) 1.05 (0.80–1.46) 1,128 32.6
≥ 60 years
2001–2002a NC < LOD 0.22 (0.13–0.35) 0.64 (0.38–1.29) 1.77 (0.76–3.10) 509 36
2001–2002a NC < LOD 0.31 (0.24–0.37) 0.68 (0.42–1.23) 1.39 (0.72–2.65) 508 36
Sex
Male
1999–2000a NC < LOD 0.25 (0.20–0.31) 0.53 (0.42–0.60) 0.79 (0.60–1.50) 947 46.8
2001–2002a NC < LOD 0.16 (0.12–0.21) 0.49 (0.41–0.64) 1.03 (0.70–1.31) 1,429 31.6
1999–2000b NC < LOD 0.22 (0.18–0.26) 0.41 (0.35–0.57) 0.80 (0.51–1.11) 947 46.8
2001–2002b NC < LOD 0.19 (0.17–0.21) 0.41 (0.33–0.47) 0.74 (0.62–1.05) 1,429 31.6
Female
1999–2000a NC < LOD 0.28 (0.22–0.38) 0.68 (0.49–1.08) 1.47 (0.95–2.54) 1,004 46.6
2001–2002a NC < LOD 0.19 (0.12–0.25) 0.56 (0.40–0.74) 0.90 (0.79–1.13) 1,619 33.2
1999–2000b NC < LOD 0.2 (0.27–0.34) 0.63 (0.47–1.33) 1.55 (1.00–2.03) 1,004 46.6
2001–2002b NC < LOD 0.27 (0.23–0.30) 0.52 (0.46–0.63) 0.96 (0.84–1.20) 1,617 33.2
Race/ethnicity
Non-Hispanic white
1999–2000a NC < LOD 0.27 (0.22–0.34) 0.63 (0.46–0.78) 1.13 (0.74–2.35) 591 46.3
2001–2002a NC < LOD 0.16 (< LOD–0.23) 0.51 (0.38–0.76) 0.96 (0.79–1.17) 1,281 29.6
1999–2000b NC < LOD 0.31 (0.28–0.40) 0.83 (0.55–1.33) 1.55 (1.06–1.99) 591 46.3
2001–2002b NC < LOD 0.28 (< LOD–0.32) 0.63 (0.50–0.71) 1.14 (0.96–1.38) 1,280 29.6
Mexican American
1999–2000a NC < LOD 0.20 (0.11–0.24) 0.46 (0.30–0.61) 0.73 (0.47–1.32) 671 35.9
2001–2002a NC < LOD 0.14 (0.11–0.18) 0.30 (0.25–0.39) 0.51 (0.38–0.64) 767 31.3
1999–2000b NC < LOD 0.14 (0.11–0.21) 0.29 (0.23–0.35) 0.40 (0.29–0.67) 671 35.9
2001–2002b NC < LOD 0.16 (0.14–0.19) 0.28 (0.25–0.30) 0.38 (0.33–0.50) 767 31.3
Non-Hispanic black
1999–2000a 0.202 (0.155–0.262) 0.16 (0.12–0.20) 0.38 (0.27–0.52) 0.82 (0.49–1.68) 1.68 (0.91–5.43) 518 61.5
2001–2002a NC < LOD 0.30 (0.24–0.37) 0.67 (0.53–0.78) 0.94 (0.77–1.37) 776 48.5
1999–2000b 0.138 (0.104–0.182) 0.11 (0.08–0.16) 0.23 (0.18–0.28) 0.46 (0.29–0.94) 1.02 (0.52–1.80) 518 61.5
2001–2002b NC < LOD 0.17 (0.14–0.20) 0.35 (0.26–0.48) 0.58 (0.37–1.39) 775 48.5
NC, not calculated (proportion of results below LOD was too high to provide a valid result). < LOD indicates less than the LOD for the uncorrected urine values, which may vary for some 
chemicals by year. n-Values may differ because some information was missing for a particular subgroup.
aVolume-based concentrations (ng/mL). bCreatinine-adjusted concentrations (μg/g creatinine). Pyrethroid metabolites in the U.S. population
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Tables 3 and 4 show distribution percen-
tiles of concentrations of cis- and trans-DCCA, 
which were highly correlated with each 
other (r = 0.887; p < 0.001) and with 3PBA 
(r = 0.766; p = 0.02). However, the ratio of the 
cis- and trans-isomers of DCCA varied.
4F3PBA was detected in 3.2% and 0.6% 
of the urine samples analyzed in 1999–2000 
and 2001–2002, respectively. Similarly, 
cis-DBCA was detected in 1.3% and 0.5% 
of the urine samples analyzed in 1999–2000 
and 2001–2002, respectively. Both 4F3PBA 
and cis-DBCA were detected in too few of 
the samples tested to allow a reliable estima-
tion of their distribution percentiles and GM 
concentrations.
Discussion
Although pyrethroid insecticides have largely 
replaced organophosphorus and carbam-
ate insecticides as the most commonly used 
household insecticides, these are the first 
population-based data reported for the general 
U.S. population. Because these pesticides are 
relatively nonvolatile, the primary source of 
exposure is believed to be through diet, with 
perhaps short episodes of exposure from resi-
dential use of insect control products. Children 
had higher concentrations of pyrethroid insec-
ticide metabolites than did adolescents and 
adults. These results are consistent with many 
other pesticide-related exposures and probably 
reflect differences in diet and behaviors (e.g., 
hand-to-mouth behaviors). Non-Hispanic 
blacks had higher concentrations than did the 
other race/ethnicity groups. This observation 
could potentially be an indicator of socioeco-
nomic or housing status. Older homes and 
lower income households are likely to have 
more pests, requiring use of more household 
pesticides. Dietary differences could also 
account for the higher levels of pyrethroid 
  pesticide metabolites.
Concentrations of pyrethroid metabolites 
tended to be higher during the morning col-
lection periods than during the afternoon or 
evening collection periods. We cannot plau-
sibly explain this observation; however, this 
may underscore the need to have consistent 
collection times in future studies.
The high correlation between 3PBA and 
cis- and trans-DCCA suggests that the parent 
pesticides resulting in U.S. population expo-
sures were predominantly permethrin or cyper-
methrin, which is consistent with U.S. pesticide 
use data. The low frequency of detection of 
4F3PBA and cis-DBCA suggests that exposure 
to cyfluthrin and deltamethrin is infrequent.
Interestingly, the ratio of trans-DCCA 
and cis-DCCA varied from 0.001 to > 5,800; 
however, the vast majority of our ratios ranged 
between 3 and 4. The ratio of trans- to cis-
DCCA could vary based upon a variety of 
criteria, including product formulation, differ-
ential metabolism, different half-lives in envi-
ronmental media, different parent chemicals 
from which it was derived, exposure routes, 
and other factors.
The only population-based data on these 
metabolites were generated in Germany during 
the last decade (Becker et al. 2006; Heudorf 
and Angerer 2001; Heudorf et al. 2006). 
Generally, the U.S. population-based data are 
consistent with those from the German stud-
ies, where median values of 3PBA ranged from 
0.04 ng/mL to 0.29 ng/mL, compared with 
our median levels of 0.25 ng/mL and 0.27 
ng/mL for NHANES 1999–2000 and 2001–
2002, respectively. The frequencies of detection 
were relatively similar for cis- and trans-DCCA 
concentrations in the German studies and in 
our study of the U.S. population. 4F3PBA and 
cis-DBCA were detected more frequently in 
the German studies than in our U.S. study but 
were detected much less frequently than the 
other metabolites, similar to our data.
Table 4. Urinary concentrations of trans-DCCA in the general U.S. population, NHANES 1999–2002. 
Category/survey  
years
Selected percentile (95% confidence interval) Sample 
size (n)
Weighted 
detection (%) 75th 90th 95th
Total
1999–2000a 0.56 (0.48–0.70) 1.40 (1.17–1.77) 3.42 (2.39–5.56) 1,976 33.1
2001–2002a 0.43 (< LOD–0.56) 1.18 (0.93–1.64) 2.60 (1.85–3.58) 3,033 26.4
1999–2000b 0.70 (0.61–0.78) 1.56 (1.33–1.87) 2.65 (2.15–3.89) 1,976 33.1
2001–2002b 0.74 (< LOD–0.80) 1.47 (1.32–1.87) 2.62 (2.30–3.11) 3,031 26.4
Age group
6–11 years
1999–2000a 0.97 (0.70–10.66) 2.91 (1.76–4.19) 4.19 (2.97–11.7) 478 42
2001–2002a 0.47 (< LOD–0.76) 1.39 (1.03–1.68) 2.50 (1.55–3.54) 576 28.8
1999–2000b 0.90 (0.64–1.39) 1.85 (1.17–3.77) 3.67 (1.55–9.49) 478 42
2001–2002b 0.77 (< LOD–0.97) 1.40 (1.12–2.16) 2.55 (1.50–3.11) 576 28.8
12–19 years
1999–2000a 0.71 (0.52–0.86) 2.07 (1.25–3.42) 4.28 (2.12–6.23) 675 39.2
2001–2002a 0.49 (< LOD–0.67) 1.20 (0.80–1.60) 2.01 (1.49–3.77) 826 31.3
1999–2000b 0.47 (0.38–0.55) 1.02 (0.70–1.42) 1.56 (0.96–4.02) 675 39.2
2001–2002b 0.47 (< LOD–0.58) 0.85 (0.71–1.07) 1.29 (1.00–1.63) 825 31.3
20–59 years
1999–2000a 0.50 (0.40–0.62) 1.17 (0.91–1.68) 2.94 (1.49–5.56) 823 30.4
2001–2002a < LOD 1.17 (0.85–1.85) 2.56 (1.64–4.66) 1,123 24.7
1999–2000b 0.74 (0.67–1.00) 1.75 (1.29–2.26) 3.13 (2.22–4.48) 823 30.4
2001–2002b < LOD 1.87 (1.37–2.33) 2.89 (2.34–3.50) 1,123 24.7
≥ 60 years
2001–2002a 0.46 (< LOD–0.63) 1.13 (0.76–2.44) 4.27 (1.20–6.49) 508 27.9
2001–2002a 0.86 (< LOD–0.97) 1.92 (1.30–2.71) 3.31 (2.03–5.33) 507 27.9
Sex
Male
1999–2000a 0.56 (0.50–0.67) 1.28 (1.11–1.63) 2.25 (1.55–5.10) 961 33.7
2001–2002a 0.42 (< LOD–0.50) 1.12 (0.86–1.58) 2.44 (1.69–3.70) 1,419 26.1
1999–2000b 0.57 (0.50–0.67) 1.23 (1.05–1.35) 2.15 (1.53–2.74) 961 33.7
2001–2002b 0.57 (< LOD–0.61) 1.22 (1.00–1.45) 2.33 (1.68–2.73) 1,419 26.1
Female
1999–2000a 0.55 (0.41–0.82) 1.77 (1.07–3.08) 4.19 (3.08–6.81) 1,015 32.6
2001–2002a 0.44 (< LOD–0.63) 1.23 (0.91–1.98) 2.62 (1.90–3.58) 1,614 26.7
1999–2000b 0.88 (0.72–1.11) 1.87 (1.47–2.37) 3.65 (2.26–5.94) 1,015 32.6
2001–2002b 0.85 (< LOD–0.95) 1.75 (1.47–2.15) 2.98 (2.55–3.20) 1,612 26.7
Race/ethnicity
Non-Hispanic white
1999–2000a 0.56 (0.46–0.73) 1.41 (1.14–2.14) 3.89 (2.14–6.43) 595 32.7
2001–2002a 0.41 (< LOD–0.58) 1.18 (0.85–1.85) 2.64 (1.85–4.27) 1,278 25.5
1999–2000b 1.00 (0.76–1.12) 2.15 (1.65–2.74) 4.48 (2.64–6.29) 595 32.7
2001–2002b 0.88 (< LOD–0.99) 2.14 (1.57–2.33) 3.16 (2.63–3.50) 1,277 25.5
Mexican American
1999–2000a 0.47 (0.41–0.53) 1.23 (0.83–1.60) 1.87 (1.49–3.35) 691 30.2
2001–2002a 0.41 (< LOD–0.51) 0.86 (0.68–1.14) 1.57 (1.08–2.01) 767 25.8
1999–2000b 0.52 (0.44–0.64) 1.01 (0.80–1.17) 1.47 (1.17–1.69) 691 30.2
2001–2002b 0.59 (< LOD–0.67) 1.04 (0.90–1.17) 1.40 (1.17–1.87) 767 25.8
Non-Hispanic black
1999–2000a 0.78 (0.49–1.13) 1.84 (1.08–4.69) 4.69 (1.41–14.5) 518 41
2001–2002a 0.59 (0.49–0.74) 1.26 (1.05–1.70) 2.25 (1.54–3.32) 764 36.7
1999–2000b 0.50 (0.41–0.68) 1.08 (0.76–2.15) 2.15 (1.16–3.96) 518 41
< LOD indicates less than the limit of detection for the uncorrected urine values, which may vary for some chemicals 
by year. The 50th percentile measures were all < LOD and are not shown here. GMs were not calculated (proportion of 
results below limit of detection was too high to provide any valid results). n-Values may differ if some information was 
missing for a particular subgroup.
aVolume-based concentrations (ng/mL). bCreatinine-adjusted concentrations (μg/g creatinine). Barr et al.
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Interestingly, Schettgen et al. (2002) 
evaluated the population-based levels of 
3PBA and the DCCA isomers along with 
other exposure factors and concluded that 
the German population-based concentra-
tions were likely from dietary exposure. We 
can speculate a similar source for our U.S. 
popula  tion-based data; however, supplemen-
tary dietary exposure data must be obtained 
to verify this supposition. Because residential 
exposures are likely periodic and vary over 
time, our large population sample probably 
minimized the contribution of these “spikes” 
in exposure, leaving baseline exposure con-
centrations, likely from the continual dietary 
contributions to pyrethroid exposures.
Conclusions
We report the first population-based biomoni-
toring data for pyrethroid metabolites for the 
U.S. population for the period 1999–2002. 
Pyrethroid pesticide exposure appears wide-
spread, likely because of a shift in home 
pesticide use from the organophosphorus 
insecticides. Our data show that non-Hispanic 
blacks have significantly higher concentrations 
than do non-Hispanic whites and Mexican 
Americans of a common pyrethroid metabo-
lite (3PBA) in the 2001–2002 survey period 
and in the combined 4-year survey period 
but not in the 1999–2000 survey period. 
Children had significantly higher concentra-
tions of 3PBA than did adolescents in both 
NHANES survey periods and than did adults 
in NHANES 1999–2000. These data will be 
useful to establish reference range concentra-
tions for these metabolites and for evaluating 
changes in pyrethroid exposure over time in 
the United States. The U.S. population-based 
levels we found are comparable to the levels 
found in studies conducted in Germany.
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